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INTRODUCTION
Traumatic brain injury (TBI) is a leading cause of mortality and mor-
bidity in both industrialized and developing countries, being of 
greater importance in poorer countries.1,2 TBI is frequently referred 
to as the “silent epidemic” because beyond symptoms such as 
paralysis, additional complications affecting intellectual ability, 
sensation, language, and emotion may not be readily apparent. In 
fact, studies that included several European countries showed that 
TBI resulted in one of the highest injury burden pathologies due to 
permanent disability,3 and among the highest costs for health sys-
tems.4 Extensive efforts have been made to develop neuroprotec-
tive therapies for this devastating disorder, but despite interesting 
preclinical results, no successful outcomes have been observed in 
human clinical trials to date.1,2 Following an initial mechanical insult, 
focal TBI results in complex delayed secondary progressive injury 
due to anatomical, neurochemical, metabolic, inflammatory, and 
cellular changes that account for many of the neurological deficits 
observed.1,2,5
The introduction of functional genes into an organism for treat-
ing or correcting a range of pathologies has emerged in the past 
few decades as a powerful tool.6,7 Worldwide, over 1,800 gene 
therapy clinical trials are either ongoing or have been approved.8 
Thirty-six of these trials involve using different gene therapy vectors 
for treating chronic disorders of the central nervous system (CNS).8,9 
One main focus in gene therapy research is the development of 
appropriate delivery systems,6,7,10 which can be complicated and 
is considered to be a bottleneck for achieving desired clinical out-
comes. Viral vectors tend to be the most effective carriers of nucleic 
acids into foreign cells, as they are evolutionary optimized for this 
purpose. One of the most popular types of viral vectors being 
developed for treating CNS disorders are HIV 1-derived lentiviral 
vectors.11,12 They have been tailored in recent years to have reduced 
biological risk and to have features that make them excellent deliv-
ery vehicles including applications for treating CNS disorders. These 
vectors are safe, have low immunogenicity and transduce postmi-
totic cells.13–15 Nonintegrating lentiviral vectors, in particular, show 
promising features for use in treating CNS disorders.16,17 Nonviral 
vectors have also gained attention,6,7,10,18 and in particular, vehicles 
based on multifunctional proteins in DNA complexes. These vec-
tors constitute a very versatile type of carrier for therapeutic nucleic 
acids, constructed by combining appropriate functional domains 
fused as a single polypeptide chain.19 This approach has generated 
the first prototypes of modular recombinant protein nanovectors 
where the integrated domains enable the construct to mimic an 
infective viral cycle. In this way, delivery of nucleic acids is effectively 
targeted. This type of nanoparticle has also been termed “artificial 
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Traumatic brain injury (TBI) remains as one of the leading causes of mortality and morbidity worldwide and there are no effective 
treatments currently available. Gene therapy applications have emerged as important alternatives for the treatment of diverse 
nervous system injuries. New strategies are evolving with the notion that each particular pathological condition may require a 
specific vector. Moreover, the lack of detailed comparative studies between different vectors under similar conditions hampers 
the selection of an ideal vector for a given pathological condition. The potential use of lentiviral vectors versus several modular 
protein-based nanovectors was compared using a controlled cortical impact model of TBI under the same gene therapy conditions. 
We show that variables such as protein/DNA ratio, incubation volume, and presence of serum or chloroquine in the transfection 
medium impact on both nanovector formation and transfection efficiency in vitro. While lentiviral vectors showed GFP protein 1 
day after TBI and increased expression at 14 days, nanovectors showed stable and lower GFP transgene expression from 1 to 14 
days. No toxicity after TBI by any of the vectors was observed as determined by resulting levels of IL-1β or using neurological sticky 
tape test. In fact, both vector types induced functional improvement per se.
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virus”.6,10 The modular nature of such constructs allows for selection 
and incorporation of well-characterized peptides with different fea-
tures so as to improve function by iteratively redesigning the con-
struct.18,20 Several nanovectors of this type can be successfully used 
to transfect cells in vitro10,21–25 and to result in the expected thera-
peutic effect when used in vivo.26–29 There is thus great interest in 
developing the potential of these nanovectors for use in a clinical 
context. One such modular nanovector, i.e., NLSCt, is based on a tet-
rameric carrier protein including β-Galactosidase engineered with a 
polylysine K10 tail which binds to and condenses DNA, a NLS motif 
for nuclear localization and an prototypic integrin-interacting RGD 
domain, which binds to membrane integrins to promote cell inter-
nalization.30 This vector was shown to induce biologically relevant 
concentrations of transgenic protein after acute excitotoxic brain 
injury.26,28,31,32 The NLSCt protein RGD interacting motif could induce 
neuroprotection per se raising the interesting possibility of utilizing 
vector functional motif activities to rapidly direct neuroprotective 
actions on the specific target.26,27 The modular principles underly-
ing the NLSCt vector were further improved by generating two 
smaller nanovectors termed HKRN and HNRK. These polypeptides 
are based on alternative combinations in a single small polypep-
tide of domains RGD, NLS, and K10 and an additional poly-histidine 
domain H6 that provides for endosomal escape and is also useful 
for purification of these constructs. These nanovector constructions 
could be used to achieve significant levels of transgene expression 
in cultured cells,10 but testing in vivo transfection properties have 
not been done.
Importantly, the original hypothesis that a single very efficient 
gene therapy vector could be used for most applications has been 
revised to the idea that each particular pathological condition may 
require a specific vector. For instance, for treatment of acute trau-
matic CNS injuries, the vector should induce a rapid but not perma-
nent induction of transgene expression, it should not be proinflam-
matory as inflammation is a key mediator of neuropathology and a 
specific cell type may or may not needed to be targeted depending 
on the mechanism of action of the transgene.1,2 In addition, other 
less obvious variables have become important to consider: (i) which 
are the optimal levels of transgene expression? (ii) What is the ideal 
time window for expression? (iii) Should the vector induce wide-
spread or a localized transduction? Moreover, the lack of detailed 
comparisons of different vector types in the same model under 
identical conditions continue to hamper selection of the most 
appropriate vector for particular pathological conditions.
In this context, the aim of the present study was to quantify, 
under similar conditions, the potential of lentiviral vectors versus 
the modular recombinant nanovectors NLSCt, HNRK, and HKRN as 
gene therapy vectors for TBI. We first describe the effect of several 
variables such as protein/DNA mass ratio, incubation volume, and 
presence of serum or chloroquine in the transfection medium on 
nanovector formation and transfection efficiency in vitro. Moreover, 
using the controlled cortical impact (CCI) model for TBI, we evalu-
ated the level and time-window of transgene expression, induction 
of inflammation, and toxic effects induced by both types of vector.
ReSUlTS
Modular protein nanovectors HNRK and HKRN were incubated 
with plasmid DNA at room temperature, to generate self-organized 
nanoparticles of ca. 80 nm.10 Since different protein/DNA mass 
ratios can result in different transfection efficiencies,10 we analyzed 
transfection efficiency of HNRK and HKRN vectors formed at dif-
ferent protein/DNA mass ratios. This was done taking into account 
that protein/DNA mass ratios of 2.5 and 1.5 of HNRK and HKRN, 
respectively, result in complete retardation of total DNA in the 
sample in gel retardation assays.10 HEK293T cells were incubated 
with nanovectors loaded with 2 μg of a GFP-expressing plasmid 
transcriptionally controlled by a CMV promoter. Percentage of cells 
transfected and the relative fluorescence intensity/cell were ana-
lyzed 24 hours after transfection. The HNRK and HKRN vectors puri-
fied from bacterial inclusion bodies had increased transfection effi-
ciency when compared to the same vectors purified from soluble 
bacterial fractions (HNRKs), or when compared to the similar vector 
NLSCt or to naked DNA (Figure 1a). Increased protein/DNA mass 
ratios in nanocomplexes formed resulted in increased transfec-
tion efficiency with optimal ratios of 4.5–5 (Figure 1a), and declin-
ing efficiency at higher ratios thereafter (not shown). Interestingly, 
although a higher percentage of cells were transfected with lipo-
fectamine than with HNRK or HKRN nanocomplexes, relative fluo-
rescence intensity/cell was similar for the three groups at 4.5–5 pro-
tein/DNA mass ratios (Figure 1b). Also, there was no decrease in cell 
viability after treatment with nanocomplexes (not shown). We next 
transduced HEK293T cells with third-generation lentiviral vectors 
pseudotyped with VSV envelope protein. These vectors carried the 
same expression cassette used in the nanovector transfection assay, 
and were analyzed 1 and 3 days post-transfection/transduction 
(dpt) for percentage of cells transduced and for relative fluorescence 
intensity/cell. Transfection of cells with HNRK or HKRN resulted in 
maximal transgene expression at 24 hours (not shown), however 
and as previously reported lentiviral vectors required at least 3 days 
for full transgene expression (Figure 1c,d).16 Surprisingly, GFP was 
detected as early as 1 dpt for all multiplicities of infection (MOIs) 
tested. Cell toxicity was observed at 3 dpt for the highest MOI tested 
(i.e., MOI = 4.4, data not shown). HEK293T cell transduction effi-
ciency, however, was higher for lentiviral vectors (at MOI 1, there 
are 1.4 × 106 to 1.4 × 107 copies of the gfp gene in transduced cells 
according to QPCR data derived calculations in ref. 33) compared 
with the nanovectors (the 2 μg DNA used per well corresponds to 
2.4 × 1011 copies of gfp gene) in terms of percentage of transduced 
cells (Figure 1a–d). In terms of relative fluorescence intensity/cell, 
qualitative microscopic observations confirmed the increased 
intensity after lentiviral transduction when compared to nanovec-
tor transfection. Comparative quantitative data are shown in Table 1.
Transfection efficiency of nanovectors for applications in gene 
therapy relies on their ability to escape endosomes after being 
endocytosed. We show that transfection efficiency with both 
HNRK and HKRN can be increased, especially the HNRK vector, 
using the prototypical endosome destabilizing agent chloroquine 
(Figure  2a,b). Serum proteins are another factors known to affect 
transfection efficiency for different vectors.34 We show that the pres-
ence of 10% serum during transfection of HEK293T cells results in an 
~40 and 35% decrease in the transfection efficiency for HNRK and 
HKRN, respectively (Figure 2c,d).
Another limiting factor for in vivo administration of these vec-
tors is the volume that can be injected into CNS parenchyma due 
to very limited extracellular space. Thus, we evaluated the effect of 
nanocomplex formation in a reduced volume. A reduction in nano-
complex formation volume, i.e., from 200 to 30 µl OPTIPRO medium, 
however, resulted in 52 and 42% decreases in HEK293T cell trans-
fection efficiency for HNRK and HKRN nanovectors, respectively 
(Figure 3a,b). Another important variable that can affect nanocom-
plex formation and transfection efficiency is protein/DNA incuba-
tion time. Analysis of HNRK/DNA nanocomplex particles formed 
using dynamic light scattering (DLS) and transmission electron 
microscopy (TEM) indicated particle size tended to be less variable 
when produced in 200 μl OPTIPRO medium compared with being 
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produced in 30 μl phosphate-buffered saline (PBS), the vehicle 
used for in vivo administration of vectors (Figure 3c,d). There were 
no significant differences in nanocomplex formation with either 
20 minutes or 5 hours incubation times for either condition (200 µl 
OPTIPRO or 30 μl PBS). Accordingly, no differences were observed 
in HEK293T cell transfection efficiency of HNRK/pDNA nanovectors 
Figure 1  In vitro transfection and transduction efficiency of vectors. HEK293T cells were incubated for 4 hours with DNA, lipofectamine (LIPO), or 
modular protein nanovectors at different protein/DNA mass ratios (ratios from 2.5 to 7.5 are shown), and transfection efficiencies (a) and relative 
fluorescence intensity per cell (b) were quantified 1 day later by flow cytometry. DNA concentrations used (2 μg/well, 2.4 × 1011 copies of gfp gene) 
were the same in all cases so as to compare transfection efficiencies. HNRK and HKRN vectors were purified from insoluble bacterial fractions and 
compared with HNRK obtained from soluble bacterial fractions (HNRKs). In parallel experiments, HEK293T cells were incubated with lentiviral vectors at 
different multiplicities of infections (MOIs) (at MOI 1, there are 1.4 × 106 to 1.4 × 107 copies of the gfp gene) and transduction efficiencies (c) and relative 
fluorescence intensity per cell (d) were quantified at 1 and 3 days post-transduction (dpt). a, b: *P < 0.05 when compared with NLSCt, DNA, or HNRKs; 





































































































































































































































Table 1 Comparative efficiency of transfection/transduction of HEK293T cells at 3 dpt with lentiviral vectors and HNRK nanovectors
Treatment Estimated gfp 
gene copy number
% of cells expressing GFP 





Lentiviral vectors MOI 1a 1.4 × 106–1.4 × 107 100.0 ± 19.0 456.1 ± 16.2 1,593.0 ± 24.7
HNRK 10 μg + 2 μgDNA 2.4 × 1011 11.3 ± 0.4 17.1 ± 0.8 646.0 ± 31.8
HNRK 1 μg + 0 .2μgDNA 2.4 × 1010 0.4 ± 0.1 14.9 ± 1.2 240.8 ± 201.2
HNRK 0.1 μg + 0.02 μgDNA 2.4 × 109 0.2 ± 0.0 11.5 ± 0.7 89.0 ± 77.5
aThe multiplicities of infection (MOI) 1 titer obtained in HeLa cells as described in Materials and Methods and used throughout this work corresponds to titer MOI 20 
in HEK293T cells, and the latter has been used to calculate the number of gfp gene copy number.
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formed in 200 μl OPTIPRO over 20 minutes versus those formed 
over 5 hours (Figure 3e). Nanocomplex size observed by TEM and 
hydrodynamic diameter observed by DLS differed. While TEM 
images showed particles to be between 20–200 nm, DLS indicated 
particles to be between 1–2 μm suggesting clustering or aggrega-
tion of particles.
Selection of an appropriate vector for a given gene therapy appli-
cation is critical. In order to determine which vector is most suited 
for treatment of TBI, we compared several important variables of 
HNRK/pDNA nanovectors and third-generation lentiviral vectors 
under identical conditions using a CCI TBI injury model. The previ-
ously described nanovector, NLSCt/pDNA, was also included as an 
internal standard. This vector was shown to be able to induce trans-
gene expression after acute excitotoxic brain injury, and to result 
in producing significant biological effects.26,28,32,35 Comparisons of 
relative levels of GFP protein after CCI lesion were made by enzyme-
linked immunosorbent assay (ELISA) of samples from untreated 
control rats and those receiving a 4 hours delayed intraparen-
chymal injection of nanovectors NLSCt/pDNA or HNRK/pDNA or 
lentiviral vectors. GFP protein was detected in all three cases at 1 
and 14 days postlesion (dpl) (Figure 4a). The GFP level at 1 dpl was 
similar in NLSCt/pDNA and HNRK/pDNA injected animals, tend-
ing to decrease in NLSCt/pDNA-treated animals but to increase in 
HNRK/pDNA treated-animals at 14 dpl. The GFP level at 1 dpl after 
lentiviral injection tended to increase compared with both NLSCt/
pDNA- and HNRK/pDNA-treated animals. There was a 100-fold 
increase in GFP protein levels comparing 1 and 14 dpl after lentivi-
ral injection. Remarkably, there was also a 100-fold increase in GFP 
expression in animals injected with the lentiviral vectors compared 
with HNRK/pDNA-treated animals at 14 dpl. GFP levels in different 
animals of the same treatment groups at 14 dpl showed significant 
differences despite carefully controlled injection procedure and use 
of same vector batches. In the case of nanovectors, due to experimen-
tal reasons, incubation time for self-assembly of protein and pDNA 
varied from 20 minutes to 4 hours. However, there was no correla-
tion for time of assembly and in vivo transgene expression (data not 
shown). Detection of HNRK vector by western blot at 1 dpl showed 
the presence of the protein in only one of four animals analyzed, indi-
cating that the vector may be rapidly degraded in vivo (not shown).
Many gene therapy vectors induce inflammation, which may 
result in toxicity due to the treatment. It is very important to 
avoid these effects in treating TBI, where inflammatory reactions 
are key responses in development of subsequent neuropathol-
ogy. Determination to what extent our vectors elicits inflamma-
tory responses is thus critical for their development. We analyzed 
levels of IL-1β, the prototypic proinflammatory marker, after CCI 
and injection of the different vectors. No significant differences 
were observed comparing vehicle-injected and nanovector-
injected animals (Figure 4b). To further evaluate possible toxic 
effects of vectors, the sticky tape functional test was performed 
to evaluate motor and sensory function (Figure 4c,d).36 As previ-
ously described, when this test was done with both nonlesioned 
animals or on the ipsilateral forepaw of lesioned animals, a very 
rapid (2–5 seconds) detection and removal of the tape results (not 
shown). After CCI, animals show increased time for detection and 
removal of the sticky tape placed on the contralateral forepaw. 
In accordance with studies on neuroprotection after excitotoxic 
brain lesions,26,27 NLSCt/pDNA-treated animals in fact displayed 
less pronounced functional compromise at 10 days after CCI 
(Figure 4c). Administration of the nanovector HNRK/pDNA also 
resulted in less pronounced functional compromise at 10 dpl. 
Interestingly, animals subjected to CCI spontaneously recovered 
from the neurological deficits measured by this test over time, hin-
dering further evaluation after 14 dpl (not shown). A very similar 
profile was observed after lentiviral vector injection, showing less 
pronounced functional compromise at 14 dpl (Figure 4d).
DISCUSSION
Detailed comparative studies for evaluating the potential of differ-
ent vectors for gene therapy treatment of specific pathologies are 
urgently needed in the current gene therapy scenario. Here, we 
evaluate two promising vector types, namely modular recombi-
nant nanovectors and lentiviral vectors, for treatment 4 hours after 
TBI using a CCI model. The gene therapy strategy involves a proto-
col similar to that used used for Parkinson’s disease clinical trials, 
including carefully controlled stereotaxic injection of a given vector 
into the brain lesion penumbra. Vectors administered in this study 
exhibited significant brain GFP protein levels 1 day after treatment 
Figure 2 Effects of chloroquine and fetal bovine serum (FBS) on transfection efficiency of protein nanovectors. HEK293T cells were incubated for 4 
hours with the modular protein nanovectors HNRK (a, c) or HKRN (b, d) in the absence or presence of the endosome disrupting agent chloroquine 
(a, b), or in absence or presence of 10% FBS (c, d). One day later, transfection efficiencies were quantified by flow cytometry. *P < 0.05 when compared 
to vectors in the absence of chloroquine or FBS.
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Figure 3 Effect of incubation volume and medium on the protein nanovector complex size and transfection efficiency. HNRK and HKRN modular 
protein nanovectors were allowed to self-assembly during a 20-minute incubation of HNRK and HKRN proteins with plasmid DNA in either 200 μl 
OPTIPRO medium or 30 μl PBS. Assembled nanovectors were then used to transfect HEK293T cells and transfection efficiencies were quantified 1 day 
later by flow cytometry (a, b). HNRK nanovector stability was analyzed after self-assembly in 200 μl OPTIPRO medium or 30 μl phosphate-buffered 
saline, and for 20 minutes to 5 hours incubation periods. The products formed were analyzed by dynamic light scattering (c) or transmission electron 
microscopy (d) as indicated. Transfection efficiency of HNRK nanovector after self-assembling in 200 μl OPTIPRO medium for 20 minutes to 5 hours was 
analyzed by flow cytometry 1 day after transfection (100% represents transfection efficiency for nanovectors formed in the 20 minutes incubation time). 
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and for at least 2 weeks. Transgene expression levels were much 
higher and more variable using the lentiviral vectors, and no appar-
ent increase in inflammation or neurodegeneration was observed 
after treatment with any of the vectors. In fact, the injection of either 
vector type per se induced functional recovery of the animals.
There remain several obstacles that need to be better under-
stood for the development of such vectors for use in therapeutic 
applications and other in vivo conditions. Direct injection of vectors 
into the brain parenchyma limits their delivery to a relatively small 
volume of tissue due to the very limited CNS extracellular space. 
Direct intraparenchymal injection of vectors into the human brain 
by stereotactic methods, as in Parkinson’s disease clinical trials, on 
the other hand can be accomplished without important permanent 
side effects or intracerebral hemorrhages, and also have resulted 
interesting clinical outcomes.37–40 In the human brain, up to 80 μl 
can be injected at a given site.37 No more that 5 μl, however, is nor-
mally injected per injection site in rat brain. To increase amount and 
distribution of vector administered in our study, three injections of 
2 μl each were administered in the anterior, lateral, and posterior 
lesion penumbra regions. In an attempt to further concentrate vec-
tor administered for a given injection, we conducted our standard 
NHRK nanovector self-assembly normally done in a 200 μl volume 
in a smaller volume of 30 μl. Self-assembly of vectors into nanopar-
ticles by combining modular protein with pDNA is a very interest-
ing and useful phenomenon enabling assembled vectors to act as 
efficient vehicles for nucleic acid transport to the cell nucleus.10,24 
Figure 4 Comparative efficiency and toxicity of protein nanovectors and lentiviral vectors after a controlled cortical impact (CCI). Four hours after 
a CCI, animals were intracortically injected with either protein nanovectors or lentiviral vectors at three locations in the lesion border (see Materials 
and Methods). At 1 and 14 days dpl, animals were sacrificed and levels of GFP protein analyzed by enzyme-linked immunosorbent assay (ELISA) 
(a, *P < 0.05 when compared to all other groups). The effect of vectors on proinflammatory responses after CCI treatment was analyzed by measurement 
of IL-1β expression levels by ELISA and compared with vehicle-treated CCI animals (b), and no significant differences were observed. The putative 
toxicity of the vectors after a CCI was evaluated by the sticky tape functional test (c, d). The mean time elapsed for removal of the sticky tape on the 
lesioned forepaw is shown for each group from 3 to 14dpl. Phosphate-bufffered saline (PBS) n = 12, Dulbecco’s modified Eagle medium (DMEM) n = 8, 
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Furthermore, and consistent with other studies,10,24 we found an 
optimal protein/pDNA mass ratio for nanovector self-assembly 
and transfection efficiency. The optimal protein/pDNA mass ratio 
for assembly and transfection efficiency was ca. 5 for both HNRK 
and HKRN protein nanovectors. There are 2,284 HNRK or HKRN pro-
teins/plasmid molecule, resulting in a predicted 7,529 net positive 
charges/nanovector molecule at physiological pH. Kenny and col-
leagues have shown that a similar anionic Neurotensin receptor tar-
geted nanovector showed increased diffusion in noninjured brain 
parenchyma when compared to its cationic counterpart.41 This sug-
gests the interesting possibility that a similar approach with our 
nanovector could increase its brain distribution. However, one has 
to consider if a widespread distribution is always desired, as under 
some conditions a specific nuclei or region of the brain may need 
to be targeted. Moreover, after acute brain injury significant edema 
occurs, potentiating diffusion of molecules in the entire lesioned 
area. Accordingly, diffusion of vector in the entire lesioned area has 
been shown for the 249AL vector, which is almost identical to the 
NLSCt vector used here.42
HNRK/pDNA or HKRN/pDNA nanocomplex formation in 30 μl PBS 
rather than 200 μl OPTIPRO resulted in the formation of complexes 
with about 50% decreased transfection efficiency using the same 
conditions for transfection of cultured HEK293T cells. This decrease 
in transfection efficiency for particles formed in the smaller volume 
correlated with higher variability in particle size as determined by 
TEM or DLS. These changes in apparent particle size may affect 
transfection efficiency and may reflect differences in pDNA compac-
tion, altered protein functional domain exposure, particle clustering 
or pDNA release from particles inside the cell. Increased particle size 
may also affect the diffusion in the lesioned brain. How variation in 
particle size may affect their transfection efficiency will require fur-
ther study. Understanding processes and mechanisms of nanocom-
plex formation might allow for refining efforts to form more uniform 
particles in smaller volumes and that have improved transfection 
efficiency. Lentiviral particle preparations do not aggregate when 
added to cell cultures,43 however comparing possible aggregation 
after intraparenchymal injection should be analyzed.
HNRK and HKRN modular proteins display a cell-targeting 
domain (RGD), a DNA attaching/condensing domain (K10 tail), a 
nuclear localization domain (NLS) and a poly-histidine tail that can 
stimulate endosomal escape. However, endosomal escape may still 
need to be improved further to increase transfection efficiency. In 
this regard, we included endosome-disrupting agent, chloroquine, 
in the cultures to evaluate putative increases in transfection effi-
ciency. Chloroquine addition indeed resulted in increased transfec-
tion efficiency for both HNRK and HKRN nanovectors, with more 
pronounced effects for the HNRK vector. This suggests engineer-
ing the HNRK vector can be further improved using other known 
endosome escaping motifs.18 Alternatively, chloroquine could be 
co-injected with assembled nanovector in vivo to increase transfec-
tion efficiency, as chloroquine has been approved for use in human 
subjects. Finally, instead of performing an intracerebral injection, 
protein nanovectors could be administered by an intravenous route 
and may reach the brain after TBI where the blood–brain barrier 
has been altered. Many vectors fail to induce significant transgene 
expression levels when combined with serum, including lentiviral 
vectors.34 Lentiviral vectors are inactivated by the serum comple-
ment system34 and vector activity decreased ~2 logs within 45 
minutes after intravenous administration.44 This problem can be 
overcome using lentivectors pseudotyped with the VSV-G protein 
subjected to directed evolution,45 or by conjugating the VSV-G 
envelope protein with poly(ethylene) glycol.44 Nonviral vectors may 
also show decreased transfection efficiency in vivo due to serum 
interactions, and the addition of different shielding molecules, 
e.g., N-succinyl-chitosan/polyethylenimine can be included to con-
tribute to enhanced stability in the presence of serum.46 Here, we 
show that the presence of 10% serum induced a 35–40% decrease in 
HEK293T cell transfection efficiency for both nanovectors. This sug-
gests that intravenous administration may need further protection 
of the vectors as described above to be an effective way to induce 
efficient transgene expression in target brain cells. Unpublished 
results from our laboratory indicate that intravenous administration 
of the NLSCt and the HNRK vector induced gfp transgene expres-
sion in several organs, but this issue needs further in vivo testing.
Only few reports have focused on gene therapy applications for 
acute CNS injuries like TBI. In some studies, expression of a protec-
tive transgene is induced prior to TBI. Minnich et al. 47, e.g., overex-
pressed GDNF with adenoviral vectors (AdV) 1 week before CCI, and 
observed neuroprotection for up to 2 weeks after.47 However, when 
GDNF AdV vectors were injected immediately after CCI, no neu-
roprotection was observed unless L-arginine was included in the 
injection administrated.48 A comparative gene therapy study using a 
fluid percussion injury TBI model was recently reported by Siddiq et 
al.49, were overexpression of a transactivator of vascular endothelial 
growth factor A using AdV and adeno-associated viral vectors was 
performed. Interestingly, the two vector types have different tem-
poral transgene expression profiles. AdV vectors show high initial 
levels of transgene expression but that is attenuated at longer time 
point,50 while adeno-associated virus (AAV) exhibit slower but long-
lasting transgene expression and as well as fewer proinflammatory 
responses.51 Siddiq et al. injected identical pfu/ml of either vector 
in 2 μl per injection site 20 minutes after the fluid percussion injury 
and observed that overexpression of VEGF-A using both vectors 
had beneficial effects, and included a 30-day functional improve-
ment mediated by AVV. In this study, different parameters for AdV 
and AVV were analyzed in treated animals precluding a comprehen-
sive comparison of the two vectors.
AdV expression of a transgene under the control of a CMV pro-
moter in the CNS was shown to peak at 4–8 days after injection 
and decline by 14 days.50 This decline in expression was found to 
be a consequence of immunological responses directed against 
cells with transgenes.52 The use of CMV promoter driven integration 
proficient and deficient lentiviral vectors16 as well as CBA promoter 
driven AVV51 for CNS transduction were shown to induce persistent 
transgene expression in immunocompetent animals, and should 
thus be useful as vectors for targeting CNS tissues. Here, we show 
that even after TBI, where inflammation is greatly potentiated by 
lesion progression, transgene expression did not decline for at least 
14 days using any of the vectors. In fact, we also found that there 
was a significant increase in transgene expression mediated by len-
tiviral vectors at 14 dpl. There was also a trend to increased expres-
sion with use of the HNRK vector compared with use of the NLSCt 
vector. An increase in transgene expression was also evident from 1 
to 3 days in lentiviral transduced HEK293T cultured cells. Dorsal root 
ganglion neurons also showed both an increase in % GFP positive 
cells and in GFP fluorescence/cell from 2 to 8 days after transduction 
using the same lentiviral system.16 In our study, however, GFP protein 
was detected at 1 dpt both in vitro and in vivo. Transgene expression 
by lentiviral vectors has not been documented previously at 1 dpt, 
and then GFP protein observed after lentiviral transduction might 
be due to carry-over during vector production or pseudotransduc-
tion. Independently of the origin of GFP, its presence at 1 dpt may 
contribute to neuroprotection after TBI, were the therapeutic win-
dow is narrow and thus a rapid treatment is essential.
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Variability in transgene expression levels despite using highly 
controlled procedures is a concern that remains difficult to resolve. 
However, data showing individual expression levels are normally 
not reported and thus further underscore the importance of this 
problem.53 We observe that lentivectors and to a lesser extent 
protein nanovectors can show significant variation in the levels of 
transgene expression. Each animal received three independent 2 
μl injections using a Hamilton syringe and an automatic nanoinjec-
tor at 0.4 μl/minute and leaving the syringe in place for 5 additional 
minutes, making it highly unlikely that, e.g., blockage of the syringe 
or reduced diffusion would account for such variation in transgene 
expression. Another potential contribution to this variability could 
be the TBI procedure or the evolution of delayed secondary pro-
gressive injury. However, injection of either integrative proficient or 
integrative deficient lentiviral vectors into nonlesioned spinal cord 
of mice and rats also resulted in some animals having high levels 
of transgene expression and others with very low levels of expres-
sion. This was seen despite use of a carefully controlled injection 
procedure and use of identical vector batches,16 as in the present 
study. Individual variations in immune responses against the trans-
gene or the vectors, or fluctuation of injections near or farther away 
from blood vessels may account for differences in GFP expression 
levels observed between animals. Taken together, this indicates 
that variability may be due to unknown technical issues or to the 
vectors, but not to TBI-related variables. Other methods like convec-
tion enhanced delivery associated with different catheters used in 
clinical trials delivering nanoparticles or viral vectors may provide 
the means for more reproducible delivery of vectors.41,54 In addition, 
no correlation was found between self-assembly reaction times for 
protein and pDNA and resulting GFP transgene expression in vivo 
(not shown). Also, no significant variation in transfection efficiency 
for HEK293T cells was found for either 20 minutes or 5 hours self-
assembly reaction times, suggesting that this variable does not 
account for the in vivo transgene level expression variations. Further 
studies need to be performed to establish to what extent variations 
in in vivo transgene expression levels are due to experimental con-
ditions in the overall gene therapy procedure in small animals or 
associated to other variables such as immune response.
The time frame for TBI treatment is short in most neuroprotective 
strategies, and thus using a gene therapy approach should involve 
vectors that rapidly express a transgene. In the fluid percussion 
injury TBI model mentioned above, where vectors were adminis-
tered 20 minutes after by intraparenchymal injection,49 AdV and 
AVV were shown to induce transgene expression at 3 days (first time 
studied) and not before 14 days, respectively. There are no other 
studies in which transgene expression response time has been 
analyzed at shorter times after acute brain injury. In this study, we 
show that both NLSCt and HNRK nanovectors and lentiviral vectors 
when administered 4 hours after CCI result in significant GFP pro-
tein levels at 24 hours after CCI. The therapeutic strategy used in this 
study includes a 4-hour interval between CCI and treatment which 
approximates the time it make take from time of TBI cranial injury to 
that of diagnosis and possible treatment in a well-organized clini-
cal context. Thus, rapid GFP transgene expression observed with 
HNRK nanovector and the presence of GFP protein after lentiviral 
vector injection induced by carry-over or pseudotransduction sug-
gests that they could provide an appropriate expression profile for 
treatment of at least the initial phases of TBI. Further comparative 
studies are needed to determine if these vectors can effectively 
provide neuroprotection after a CCI. Interestingly, nanovector 
NLSCt was reported to induce neuroprotection under different 
acute excitotoxic conditions and with different transgenes when 
injected intracortically 4 hours after lesion generation.26,28 Moreover, 
the expression of toxic transgenes with the same vector increased 
excitotoxic lesion.31,32 We report here that the HNRK vector tends to 
produce a stable level of transgenic protein until 14 dpl, while the 
lentivector induced a significant increase in the levels of transgenic 
protein up to 14 dpl. The HNRK vector could be reinjected to pro-
long the transgene expression over time, but a careful evaluation 
of the putative adaptive immune response elicited toward the vec-
tor itself should be evaluated. Taken together, these results suggest 
that both nanovectors and lentiviral vectors can result in expression 
of biological relevant concentrations of transgenic protein in vivo 
after a CCI, and provides flexibility in selection of the most appropri-
ate vector for neuroprotection after TBI.
Neuroinflammatory cascades are major contributors to second-
ary progressing injury,5 and thus additional inflammatory reactions 
promoted by gene therapy vectors may constitute a problem. We 
show here that no increase in levels of prototypical proinflam-
matory cytokine IL-1β was observed after injection of any of the 
vectors, suggesting that no further inflammation is produced. 
Moreover, no toxic effect for any of the vectors used were noted by 
the functional sticky tape test. In addition, both NLSCt and HNRK 
nanovectors exhibited functional neuroprotective effects after CCI. 
The NLSCt vector alone (not harboring pDNA) was also previously 
shown to be neuroprotective after acute excitotoxic brain injury.26 
The mechanism involved its RGD integrin-interacting motif and 
interaction with glial cells.27 In addition, the HNRK and HKRN vectors 
without pDNA were also shown to be neuroprotective for cultured 
PC12 cells.55 Thus, data presented here confirm the neuroprotec-
tive potential of these nanovectors per se in a clinically relevant TBI 
model. Surprisingly, the lentiviral vectors preparation also showed 
a significant functional neuroprotection using the sticky tape test, 
and the beneficial effects of these vector preparations without 
expressed transgenes should be studied in detail.
The lack of extensive comparative studies using several vectors 
under the same experimental TBI conditions hampers the selection 
of putative ideal vectors for clinical applications. Our study aimed 
to contribute to this important clinical need by comparing two 
of the most promising prototypes, i.e., modular nanovectors and 
lentiviral vectors. Our data indicates that both the HNRK protein 
nanovector and the lentiviral vectors are very useful prototypes for 
gene therapy applications for treatment of TBI due to the rapid and 
non-toxic and non-proinflammatory expression of a transgene. As 
already stated, this is not the case for AAV which need at lest 14 dpt 
to show the presence of the transgene.49 However, they observed 
a beneficial functional improvement at 30 dpt by overexpressing 
VEGF-A, suggesting that the selection of the ideal vector for the 
treatment of TBI must be considered in the context of the neu-
roprotective transgene of choice and its timing of expression for 
effective neuroprotection. HNRK nanovector showed rapid and 
prolonged stable expression while lentiviral vectors show slower 
and increasing levels of expression with time. As inferred from the 
limited data available for AAV in TBI models, they show a similar 
profile of time-course transgene expression as lentiviral vectors, 
with variable expression levels at different time points. The regula-
tion of expression of the transgene is critical for adjusting the dos-
age for treatment. This could potentially be achieved using induc-
ible promoters for the expression from lentiviral vectors and AAV 
as reported.56 Dosage of transgene expression driven by modular 
nanovectors would be more simple. Adenoviral vectors induce 
significant inflammatory reactions leading to the rapid elimination 
of the transgene expression in the brain.49 For this reason and due 
to the fact that the inflammatory cascades are an important part 
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of the physiopathology of TBI, these vectors may not be adequate 
for the treatment of TBI. Neither of the vectors tested here contrib-
uted strongly to the neuroinflammation provoked by CCI, a pro-
file probably shared by AAV, suggesting that they are all suitable 
for the treatment of TBI. Vectors can also be expected to differ in 
terms of cell tropism, which again should be carefully considered in 
context of the mechanism of action of the selected transgene. All 
three vectors have a broad tropism that can in addition be modu-
lated by surface protein domains, and are for thus useful vectors. 
Some AAV serotypes have been shown cross the blood brain bar-
rier, and thus having good potential for TBI treatment by intrave-
nous administration.57 On the other hand, local intraparenchymal 
injection of the vectors for TBI treatment may be a wiser choice to 
avoid intravenous injection of high titers of vectors that may have 
a negative impact. Taken together, one or more of these vectors 
may prove to be suitable for the treatment of TBI, but its choice 
should consider the specific neuroprotective mechanism of the 
transgene used. Importantly, critical properties for development 
of vectors as clinical formulations have to be taken into account. 
The ability of these nanovectors to readily self-assemble at room 
temperature self-assembly with no effect of incubation times on 
nanovectors transfection efficiency is an important step toward 
this goal. Also these vectors are noninfective, and the protein can 
be lyophilized with no loss of activity. In this regard, these vec-
tors would be of better choice over the viral vectors if the mech-
anism of action of the neuroprotective transgene involves rapid, 
short-term and low expression levels. However, if a long-term and 
high-level expression is needed to achieve neuroprotection, both 
non-integrated lentiviral and AVV may prove to be more suitable. 
Finally, the functional improvement observed by the modular nan-
ovector and the lentiviral vector preparations per se opens the way 
for the design of additional combinatorial tools for neuroprotection.
MATeRIAlS AND MeTHODS
Nanovector production and purification
The production of both chimerical proteins HKRN and HNRK, cloned in plas-
mid pET-28a (+)TEV, was induced with addition of 1 mmol/l Isopropyl β-D-1-
thiogalactopyranoside (IPTG) to plasmid-containing BL21 (DE3) Escherichia 
coli cell cultures (at OD600 nm = 0.4–0.6) growing in Luria–Bertani medium 
(Sigma-Aldrich, Chemie Gmbh Munich, Germany) at 37 °C. After 4 hours, 
cells were harvested by centrifugation, washed with PBS, and stored at −80 
°C. The pellet was suspended in lysis buffer, 20 mmol/l Tris-HCl pH 8.0, 500 
mmol/l NaCl, 6 mol/l guanidinium chloride, and cells were disrupted by 
sonication in the presence of ethylenediaamene tetra acetic acid (EDTA)-
free protease inhibitor cocktail tablets (Sigmafast Cat. Nº s8820, Sigma-
Aldrich). The soluble fraction was obtained by centrifugation at 15,000 g for 
45 minutes at 4 °C and further purified using 0.22 μm filters. Proteins were 
purified in a single step using Ni2+affinity chromatography by ÄKTATM FPLC 
(GE Healthcare, Uppsala, Sweden). After loading samples onto the column 
in 20 mmol/l Tris-HCl pH 8.0, proteins were eluted using a 20 CV linear gra-
dient to 100% elution buffer 20 mmol/l Tris-HCl pH 8.0, 500 mmol/l NaCl, 
6 mol/l guanidinium chloride, and 1 mol/l imidazole. Protein-containing 
fractions were pooled and passed through a PD-10 desalting column (GE 
Healthcare) with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-buff-
ered saline and quantified by bicinchoninic acid method. Production and 
purification of the soluble form of HNRK was performed as described above 
but using the soluble bacterial fraction and in the absence of guanidinium 
chloride. The NLSCt vector production was induced with the addition of 
1 mmol/l IPTG to plasmid-containing BL21 (DE3) E. coli cells (at OD600 nm 
= 0.4–0.6) growing in Luria–Bertani medium at 37 °C. After 4 hours, cells 
were harvested by centrifugation, washed with PBS, and stored at −80 °C. 
The bacterial pellet was suspended in TM buffer (0.44% m/v Tris + 0.4% 
m/v MgCl2 pH 7.5), and cells were disrupted by sonication in the presence 
of EDTA-free protease inhibitor cocktail tablets. The soluble fraction was 
separated by centrifugation at 15,000 g for 30 minutes at 4 °C and filtered 
through 0.22 μm filters. The vector was purified by column chromatogra-
phy using 4% p-aminobenzyl 1-thio-β-D-galactopiranoside immobilized 
to agarose (Sigma-Aldrich, Nº A0414), which was washed and equilibrated 
with 20 CV TM buffer. Elution was done using tetraborate buffer pH 10 
(3.81% m/v Na2B4O7) supplemented with β-mercaptoethanol (0.2% v/v). 
Protein-containing fractions were identified using β-galactosidase activity, 
pooled and desalted on a PD-10 column (GE Healthcare) using 0.05 mol/l 
PBS pH7.5 and quantified by the bicinchoninic acid method. Finally, all puri-
fied proteins were stored at −80 °C until use.
Lentiviral vector production and concentration
Third-generation self-inactivating HIV-1-based vectors were produced by 
transient co-transfection of four endotoxin-free plasmids (Endo Free plas-
mid Maxi kit cat. Nº 12362, Qiagen, SP, Brazil) in 293T cells as described.16 
The transfer plasmid (pRRLs in_PPT_CMV_GFP which includes an H1-driven 
shRNA empty cassette that is incorporated in virus particles, 7,657 bp) was 
based on the SIN-18 pRRL backbone. This incorporates minimal HIV ele-
ments and produces self-inactivating (SIN) vectors through 3′-LTR trunca-
tion. The packaging plasmids were pRSV-rev (Addgene, Cambridge, MA, 
cat. Nº 12253) and pMDLg/pRRE (Addgene, cat. Nº 12251). Vectors were 
pseudotyped with a standard vesicular stomatitis virus G glycoprotein 
(VSV-G; plasmid pMD2.G) (Addgene, cat. Nº 12259). Cells were cultured in 
Dulbecco’s modified Eagle medium (DMEM) with 10% fetal bovine serum 
(Invitrogen, San Diego, CA), penicillin (100 IU/ml), and streptomycin 
(100 mg/ml) in a 37 °C incubator with 5% CO2. The medium was changed 30 
minutes prior to transfection using a standard calcium phosphate transfec-
tion protocol. After 17 hours incubation, the medium was replaced by fresh 
DMEM supplemented with 10% fetal bovine serum and 4 mmol/l caffeine to 
increase viral titer. At 36 and 60 hours post-transfection, medium was har-
vested, cleared by low-speed centrifugation (2,500 rpm, 10 minutes, 4 °C), 
and filtered using 0.22 μm pore filters. Vector particles were concentrated 
by ultracentrifugation at 50,000 g for 2 hours at 4 °C. Pellets obtained were 
suspended in serum-free DMEM medium supplemented with 10 mmol/l 
MgCl2 and 5 U/ml RNAse free DNAse I (Promega, Madison, WI), incubated 
30 minutes at 37 °C and stored at −80 °C until use. Vectors were titrated by 
transducing HeLa cells with serial dilutions of vector stock in the presence 
of 8 μg/μl of Polybrene (Sigma-Aldrich), and GFP expression was analyzed 
by flow cytometry analysis 3 days post-transduction. The lentiviral titer 
obtained was 3.12 × 107 Tu/ml.
Dynamic light scattering
The size of protein/DNA complexes, formed at different incubation 
times, was determined using a DLS analyzer (Zetasizer Nano ZS, Malvern 
Instruments, Malvern, UK) at 633 nm. Samples were examined in triplicate 
and data analyzed using Malvern Zetasizer software v7.03.
Transmission electron microscopy
Protein/DNA complexes were also analyzed by TEM. Briefly, 10 μl of sample 
was put on a carbon coated grid and after 2 minutes negatively stained with 
10 μl 2% uranyl acetate (w/v). Analysis was done using a JEM-1400 transmis-
sion electron microscope (Toyoko, Japan).
Nanovector self-assembly and transfections
The pRRLs in_PPT_CMV_GFPpre endotoxin-free vector described above 
and having the GFP marker to monitor transfection efficiency, was also 
used for construction of nanovectors. HKRN/pDNA and HNRK/pDNA nano 
complex self-assembly was done using individual 5 minutes incubations 
with different amounts of protein in 100 μl OPTIPRO medium (GIBCO Life 
Technologies, GrandIsland, NY) and 2 μg plasmid DNA in 100 μl OPTIPRO 
medium. Protein/DNA complexes were generated by mixing 100 μl DNA and 
100 μl protein at specified ratios, and incubating at room temperature for 
20 minutes or indicated times.10 The 200 μl mixture was then administered 
to Hek293T/17 cells (Invitrogen, Carlsbad, CA) in 24-well plates grown to 
70–80% cell confluence for 4 hours in the absence of serum. Subsequently, 
the medium was changed to include serum and cells were incubated for an 
additional 20 hours. Chloroquine 200 mmol/l (C6628, Sigma Aldrich) or 10% 
of fetal bovine serum (GIBCO Life Technologies) were added to the cells at 
the moment of incubation with the protein/pDNA nanocomplexes to test 
the ability of complexes to escape endosomes and to transfect cells in the 
presence of serum respectively. Transfection efficiency of nanocomplexes 
formed in smaller volumes was also tested. Complex self-assembly in these 
cases was done with identical ratios and quantities of protein and pDNA 
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as used in the 200 μl final volume experiments above but in 30 μl PBS. The 
transfection efficiency was quantified 24 hours after transfection using GFP 
reporter gene expression analyzed by flow cytometry in the FACSCalibur 
system using CellQuest software (BD Biosciences, Franklin Lakes, NJ). Results 
obtained when samples were visualized by fluorescence microscopy were 
consistent with flow cytometry gene expression analysis and negative con-
trols (untreated cells and cells with plasmid only).
Animals, controlled cortical impact model, and vector injections
All experimental work was approved by Comisión Nacional de 
Experimentación Animal and the CHEA-UDELAR ethical commission, and 
conducted according to directives of the Federation of Laboratory Animal 
Science Associations. Adult male Wistar rats (280–300 g) were submitted 
to CCI traumatic lesions under 3% isoflurane anesthesia and O2 (Abbott, 
Abbott Park, IL) as described previously.36 Briefly, rats were mounted 
in an injury device stereotaxic frame in prone position and secured by 
ear and incisor bars. The head was held in horizontal plane, and a mid-
line incision was made aseptically in which soft tissues were reflected, 
and a 4 mm round craniotomy was made over the right primary motor 
and somatosensory cortex (coordinates to the center of the craniotomy: 
AP: Bregma, L: −1.7 mm). A stereotaxic mounted cortical impactor 
(PinPoint PrecisionCortical ImpactorModel PCI3000 Hatteras Instruments, 
Cary, NC) was used with a 3-mm diameter tip (velocity: 1.5 m/s, contu-
sion depth: 4-mm, contusion time: 120 ms). Four hours later, 6 μl of 
vehicle (PBS or DMEM/10 mmol/l MgCl2), lentivector (titer: 3.12 × 10
7 Tu/
ml, in DMEM/10 mmol/l MgCL2), and protein vectors accommodating 
an expression plasmid assembled in PBS (NLSCt protein/DNA ratio 33.3, 
0.14 μg DNA per animal, or HNRK ratio 5 both, 1.44 μg DNA per animal) 
were injected using a stereotaxic mounted nanoinjector (Quintessential 
Stereotaxic Nanoinjector, Stoelting CO, Wood Dale, IL) at 0.4 μl/minute 
in three locations (2 μl per site) corresponding to the anterior, right, and 
posterior lesion border (in all cases, ventral: −2mm) using a 5 μl Hamilton 
syringe. The needle was left in place for an additional 5 minutes to allow 
diffusion into the brain parenchyma. Studies were designed to random-
ize treatments and to include two or three different treatments for each 
surgical procedure.
Functional behavioral outcome measure: sticky tape test
The behavioral studies were performed at 3, 7, 10, and 14 days after CCI as 
described previously.36 All tests were performed and analyzed by individuals 
blind to the experimental conditions. A 0.5-inch diameter round adhesive 
tape was placed on the heel of each forepaw and the time it took the ani-
mal to remove the tape from each paw was recorded. Three trials were per-
formed and the average value was calculated for each rat. Individual trials 
were timed out at 3 minutes.
Sample processing and ELISA
GFP and IL-1β protein were quantified using commercially available ELISA 
kits: GFP ELISA kit (Abcam, cat. Nº #ab117992, Cambridge, MA, USA) and rat 
IL-1β ELISA kit (Invitrogen, cat.Nº #KRC0011) according to the manufacturer’s 
instructions. Rats were sacrificed at the indicated days post lesion (dpl) by 
decapitation under deep pentobarbital anesthesia. Ipsilateral brain hemi-
spheres were immediately removed and dissected to obtain fragments of 
7 × 8 × 9 mm containing the injured area, frozen in liquid nitrogen and stored 
at −80 °C. Homogenization was done in a Potter homogenizer in ice-cold 
50 mmol/l Tris-50, 1 mmol/l EDTA, pH 8.0 containing a cocktail of protease 
inhibitors (Roche, Manheim, Germany) and a phosphatase inhibitor (10 
mmol/l sodium orthovanadate, Sigma-Aldrich). The preparation was then 
cleared by centrifugation. Total protein concentration of samples was deter-
mined using the bicinchoninic acid method and identical protein concentra-
tions were used for all ELISA measurements.
Data processing and statistical analysis
All results are expressed as mean ± standard error of the mean. Student’s 
t-test was used to determine significant differences (P < 0.05) between two 
experimental groups after determination of the normal distribution of the 
samples and variance analysis. Two-way analysis of variance followed by 
Bonferroni’s multiple comparison test was used to determine significant dif-
ferences (P < 0.05) for experimental settings with more than two experimen-
tal groups or time points.
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